Biogen Anti-LINGO MS Study Failure Removes Upside
Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.
You may also be interested in...
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.
CEO George Scangos built Biogen into an innovative biotech, but his departure, coming as the company dusts itself off after a fall from glory, increased speculation Biogen could become a takeout target.